Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.

No definition available.

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of revenue that is not accounted for under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RevenueNotFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Closing stock price

+ References

No definition available.

+ Details

Name:	vir_ClosingStockPrice
Namespace Prefix:	vir_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Common Stock, Shares Issued, Fair Market Value

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesIssuedFairMarketValue
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Common Stock, Shares Purchased

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesPurchased
Namespace Prefix:	vir_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Common Stock, Shares Purchased , Aggregate Purchase Price

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesPurchasedAggregatePurchasePrice
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Common Stock, Shares Purchased, Share Price

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesPurchasedSharePrice
Namespace Prefix:	vir_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Grant Agreement, Unrecognized Premium Balance

+ References

No definition available.

+ Details

Name:	vir_GrantAgreementUnrecognizedPremiumBalance
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Grant Agreement, Unused Grant Funds Returned

+ References

No definition available.

+ Details

Name:	vir_GrantAgreementUnusedGrantFundsReturned
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Underlying shares, Premium received

+ References

No definition available.

+ Details

Name:	vir_UnderlyingSharesPremiumReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=vir_GatesFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Grant Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended	12 Months Ended
	Jan. 13, 2022	Jun. 30, 2026	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities		$ 77,207	$ 77,207	$ 83,012
Restricted cash and cash equivalents, current		1,929	1,929	1,922	$ 88,218
Vaccinal Antibody Grant \| Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Other revenue		0	0
Vaccinal Antibody Grant \| Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares purchased (in shares)	881,365
Common stock, shares purchased price (in USD per share)	$ 45.38
Common stock, shares purchased, aggregate purchase price	$ 40,000
Common stock, shares issued, fair market value	$ 28,500
Closing stock price (in USD per share)	$ 37.65
Premium received	$ 11,300
Unrecognized premium		9,100	9,100
Unused grant funds returned				9,500
Restricted cash and cash equivalents, current		1,800	1,800	$ 1,800
Vaccinal Antibody Grant \| Gates Foundation \| Balance Sheet Location: us-gaap:AccruedLiabilitiesAndOtherLiabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized premium		4,900	4,900
Vaccinal Antibody Grant \| Gates Foundation \| Balance Sheet Location: us-gaap:OtherLiabilitiesNoncurrent
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unrecognized premium		$ 4,200	$ 4,200